This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
GTx, Inc., (GTXI), a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for serious men's health conditions, announced that the company has initiated a pivotal phase III clinical trial for ACAPODENE for the prevention of prostate cancer in high-risk men.
We care about your feedback. Let us know how we can improve your CancerCompass experience.